摘要
目的:探讨恩替卡韦治疗乙肝病毒耐药导致慢性重型肝炎患者的效果。方法:收治因乙肝病毒耐药导致的慢性重型肝炎患者62例,按照随机数字表法分为对照组和观察组各31例。对照组给予基础治疗,观察组加用物恩替卡韦治疗。结果:治疗后观察组死亡率显著低于对照组(P<0.05);HBV-DNA阴转率高于对照组(P<0.05);观察组肝功能改善优于对照组,Alb水平则显著高于对照组,而ALT、AST、TBIL水平则显著低于对照组(P<0.05)。结论:恩替卡韦治疗乙肝病毒耐药导致慢性重型肝炎患者有明显疗效,利于患者死亡率的降低及HBV-DNA阴转率的升高,提高肝功能。
Objective：To explore the effect of entecavir in the treatment of hepatitis B virus resistance leading to chronic severe hepatitis.Methods： 62 patients with chronic severe hepatitis caused by hepatitis B virus resistance.They were divided into the control group and the observation group with 31 cases in each according to the random number table method.The control group was given the basic treatment.The observation group added with the entecavir treatment.Results：After the treatment,the mortality rate of the observation group was significantly lower than that of the control group（P〈0.05）;the HBV-DNA negative conversion rate was higher than that of the control group（P〈0.05）;the liver function improvement of the observation group patients was better than that of the control group,and the level of Alb was significantly higher than that of the control group,and the level of ALT,AST and TBIL were significantly lower than those of the control group（P〈0.05）.Conclusion：Entecavir in the treatment of chronic severe hepatitis caused by hepatitis B virus resistance has obvious curative effect.It is beneficial to decrease the mortality rate of the patients and increase the HBV-DNA negative conversion rate,and improve the liver function.
出处
《中国社区医师》
2016年第27期42-43,共2页
Chinese Community Doctors
关键词
慢性重型肝炎
乙肝病毒耐药
恩替卡韦
Chronic severe hepatitis
Hepatitis B virus resistance
Entecavir
